Amicus Therapeutics, Inc. (LON:0HF9)

Market Cap	3.29B +41.9%
Revenue (ttm)	445.40M +21.3%
Net Income	-10.46M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	23.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54
Average Volume	526
Open	14.59
Previous Close	14.32
Day's Range	14.30 - 14.59
52-Week Range	5.54 - 14.59
Beta	0.42
RSI	80.84
Earnings Date	Feb 18, 2026

About Amicus Therapeutics

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration an...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2002
• Employees: 499
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HF9

Financial Performance

In 2024, Amicus Therapeutics's revenue was $528.30 million, an increase of 32.29% compared to the previous year's $399.36 million. Losses were -$56.11 million, -62.99% less than in 2023.

Financial numbers in USD